glp 1 eye problems Emerging Concerns: GLP-1 Modulators and Their Potential Risk to Vision glp 1 and vision issues

2.2 GIPR agonism serves to reduce GLP-1R mediated GI AEs in the clinic Treatment with GLP-1R agonists can drive nausea, diarrhea, vomiting, and constipation, which often results in discontinuation of treatment (6-10% of patients) or reduction in dose (~15% of patients) (63)

The FDA approves at 27 with comorbidities

Persistent or recurrent infections may indicate antibiotic resistance, inadequate treatment duration, or underlying urological abnormalities requiring further investigation with imaging studies or urology referral

Preclinical investigations suggest that combining these two peptides may amplify certain laboratory endpoints beyond what is observed when either compound is examined independently

Duranay M, Akay H, Yilmaz FM, et al